Estrogen and progestagens differentially modulate vascular proinflammatory factors.

Area of Science:

• Neuroscience
• Endocrinology
• Vascular Biology

Background:

• Ovarian hormone replacement therapy shows potential benefits in cerebrovascular disease, but clinical trial results are conflicting.
• Understanding the vascular actions of estrogen (E) and progestagens like progesterone (P) and medroxyprogesterone acetate (MPA) is crucial for cerebrovascular health.
• Cerebrovascular inflammation plays a key role in ischemic brain injury.

Purpose of the Study:

• To investigate how in vivo exposure to 17beta-estradiol (E), progesterone (P), or medroxyprogesterone acetate (MPA) affects inflammation in the cerebral vasculature.
• To determine the influence of ovarian hormones on inflammatory responses in the context of ischemic brain injury.

Main Methods:

• Female rats were treated with lipopolysaccharide (LPS) to induce inflammation.
• Brains were harvested 6 hours post-LPS for cerebral blood vessel isolation.
• Western blot analysis was used to quantify inflammatory enzymes: inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).

Main Results:

• In ovariectomized rats, LPS induced cerebrovascular iNOS and COX-2, an effect significantly reduced by 3-week estrogen (E) treatment.
• Treatment with progesterone (P) or medroxyprogesterone acetate (MPA) in ovariectomized rats exacerbated the inflammatory response to LPS.
• In intact rats, LPS-induced inflammation varied with the estrous cycle, with the greatest effect during estrus (low estrogen, high progesterone).

Conclusions:

• Endogenous and exogenous ovarian hormones modulate cerebrovascular inflammation.
• Estrogen (E) exhibits anti-inflammatory effects that may attenuate ischemic brain injury.
• The vasoprotective benefits of estrogen may be diminished by the presence of progestagens (P or MPA).